Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Thymus Neoplasms 1 Neuroendocrine Tumors 1

Interventions

pembrolizumab 80 Carboplatin 73 Paclitaxel 58 Cisplatin 58 Specimen Handling 56 Magnetic Resonance Spectroscopy 56 Gemcitabine 48 Docetaxel 37 Dexamethasone 37 Oxaliplatin 34 Fluorouracil 33 Bevacizumab 33 Pemetrexed 32 Leucovorin 32 Doxorubicin 32 Cyclophosphamide 31 durvalumab 29 Radiotherapy 29 Radiation 28 Capecitabine 28 Rituximab 25 Letrozole 25 Etoposide 24 Nivolumab 23 Irinotecan 23 Vincristine 22 Taxes 21 Lenalidomide 21 Prednisone 20 Bortezomib 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × 177Lu-octreotide, DOTA(0)-Tyr(3)- × 30 days × Clear all

NCT05918302 2026-05-12

LEVEL

Grupo Espanol de Tumores Neuroendocrinos

Phase 3 Recruiting

Thymus Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡